TNGX logo

Tango Therapeutics, Inc. (TNGX) Cash From Financing

Annual CFF:

$47.66M-$34.74M(-42.16%)
December 31, 2024

Summary

  • As of today, TNGX annual cash from financing is $47.66 million, with the most recent change of -$34.74 million (-42.16%) on December 31, 2024.
  • During the last 3 years, TNGX annual cash from financing has fallen by -$309.66 million (-86.66%).
  • TNGX annual cash from financing is now -86.66% below its all-time high of $357.32 million, reached on December 31, 2021.

Performance

TNGX Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTNGXcash flow metrics

Quarterly CFF:

$2.54M+$1.96M(+337.35%)
September 30, 2025

Summary

  • As of today, TNGX quarterly cash from financing is $2.54 million, with the most recent change of +$1.96 million (+337.35%) on September 30, 2025.
  • Over the past year, TNGX quarterly cash from financing has increased by +$139.00 thousand (+5.79%).
  • TNGX quarterly cash from financing is now -99.22% below its all-time high of $327.78 million, reached on September 30, 2021.

Performance

TNGX Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTNGXcash flow metrics

TTM CFF:

$4.09M+$139.00K(+3.52%)
September 30, 2025

Summary

  • As of today, TNGX TTM cash from financing is $4.09 million, with the most recent change of +$139.00 thousand (+3.52%) on September 30, 2025.
  • Over the past year, TNGX TTM cash from financing has dropped by -$44.07 million (-91.50%).
  • TNGX TTM cash from financing is now -98.85% below its all-time high of $357.38 million, reached on September 30, 2021.

Performance

TNGX TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTNGXcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

TNGX Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-42.2%+5.8%-91.5%
3Y3 Years-86.7%+2148.7%+322.8%
5Y5 Years-41.1%-96.9%-94.9%

TNGX Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-86.7%+2851.3%-96.8%>+9999.0%-96.8%+322.8%
5Y5-Year-86.7%+2851.3%-99.2%+440.6%-98.8%+322.8%
All-TimeAll-Time-86.7%+2851.3%-99.2%+440.6%-98.8%+322.8%

TNGX Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2025
-
$2.54M(+337.3%)
$4.09M(+3.5%)
Jun 2025
-
$581.00K(>+9900.0%)
$3.95M(-15.6%)
Mar 2025
-
$2000.00(-99.8%)
$4.68M(-90.2%)
Dec 2024
$47.66M(-42.2%)
$969.00K(-59.7%)
$47.66M(-1.0%)
Sep 2024
-
$2.40M(+83.2%)
$48.16M(-61.8%)
Jun 2024
-
$1.31M(-96.9%)
$126.04M(+0.6%)
Mar 2024
-
$42.98M(+2829.9%)
$125.31M(+52.1%)
Dec 2023
$82.41M
$1.47M(-98.2%)
$82.41M(+1.2%)
Sep 2023
-
$80.28M(>+9900.0%)
$81.47M(+6171.4%)
Jun 2023
-
$586.00K(+702.7%)
$1.30M(-9.2%)
DateAnnualQuarterlyTTM
Mar 2023
-
$73.00K(-86.1%)
$1.43M(-11.4%)
Dec 2022
$1.61M(-99.5%)
$527.00K(+366.4%)
$1.61M(+66.8%)
Sep 2022
-
$113.00K(-84.3%)
$968.00K(-99.7%)
Jun 2022
-
$718.00K(+179.4%)
$328.63M(+0.4%)
Mar 2022
-
$257.00K(+314.2%)
$327.17M(-8.4%)
Dec 2021
$357.32M(+341.8%)
-$120.00K(-100.0%)
$357.32M(-0.0%)
Sep 2021
-
$327.78M(>+9900.0%)
$357.38M(+223.4%)
Jun 2021
-
-$746.00K(-102.5%)
$110.52M(-0.7%)
Mar 2021
-
$30.41M(>+9900.0%)
$111.27M(+37.6%)
Dec 2020
$80.88M
-$61.00K(-100.1%)
$80.86M(-0.1%)
Sep 2020
-
$80.92M
$80.92M

FAQ

  • What is Tango Therapeutics, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Tango Therapeutics, Inc.?
  • What is Tango Therapeutics, Inc. annual cash from financing year-on-year change?
  • What is Tango Therapeutics, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Tango Therapeutics, Inc.?
  • What is Tango Therapeutics, Inc. quarterly cash from financing year-on-year change?
  • What is Tango Therapeutics, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Tango Therapeutics, Inc.?
  • What is Tango Therapeutics, Inc. TTM cash from financing year-on-year change?

What is Tango Therapeutics, Inc. annual cash from financing?

The current annual cash from financing of TNGX is $47.66M

What is the all-time high annual cash from financing for Tango Therapeutics, Inc.?

Tango Therapeutics, Inc. all-time high annual cash from financing is $357.32M

What is Tango Therapeutics, Inc. annual cash from financing year-on-year change?

Over the past year, TNGX annual cash from financing has changed by -$34.74M (-42.16%)

What is Tango Therapeutics, Inc. quarterly cash from financing?

The current quarterly cash from financing of TNGX is $2.54M

What is the all-time high quarterly cash from financing for Tango Therapeutics, Inc.?

Tango Therapeutics, Inc. all-time high quarterly cash from financing is $327.78M

What is Tango Therapeutics, Inc. quarterly cash from financing year-on-year change?

Over the past year, TNGX quarterly cash from financing has changed by +$139.00K (+5.79%)

What is Tango Therapeutics, Inc. TTM cash from financing?

The current TTM cash from financing of TNGX is $4.09M

What is the all-time high TTM cash from financing for Tango Therapeutics, Inc.?

Tango Therapeutics, Inc. all-time high TTM cash from financing is $357.38M

What is Tango Therapeutics, Inc. TTM cash from financing year-on-year change?

Over the past year, TNGX TTM cash from financing has changed by -$44.07M (-91.50%)
On this page